Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.60 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 5/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2015408 | 0.87 | PTGS2 (0.43) | PTGS2HSD11B1PTGS1KCNH2 | |
| SCHEMBL2025893 | 0.83 | GRM5 (0.39) | PTGS2BRD4GRM5 | |
| SCHEMBL2025519 | 0.79 | HSD11B1 (0.42) | PTGS2HSD11B1PTGS1KCNH2 | |
| SCHEMBL3246596 | 0.77 | PTGS2 (1.00) | PTGS2DRD1BRD4PTGS1 | |
| SCHEMBL12575453 | 0.73 | PTGS2 (0.46) | PTGS2HSD11B1PTGS1KCNH2 | |
| SCHEMBL1676179 | 0.72 | PTGS2 (0.88) | PTGS2DRD1PTGS1SCN9A | |
| SCHEMBL2018913 | 0.70 | TNK2 (0.46) | GRM5 | |
| SCHEMBL8484099 | 0.69 | PTGS2 (0.81) | PTGS2DRD1PTGS1 | |
| SCHEMBL2020736 | 0.68 | MET (0.54) | GRM5 | |
| SCHEMBL25430418 | 0.65 | PTGS2 (0.72) | PTGS2DRD1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343977-B2 | Substituted triazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343977-B2 | Substituted triazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343977-B2 | Substituted triazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2011082271-A2 | SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160226-A1 | Substituted Triazolo-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160226-A1 | Substituted Triazolo-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160226-A1 | Substituted Triazolo-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160226-A1 | Substituted Triazolo-Pyrimidine Compounds | TYMP, TK1, DPYD | PTGS2 1375/4885DRD1 3995/4885HSD11B1 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.